New York Attorney General Letitia James sued Robert G. Kramer, former CEO of Emergent BioSolutions, for insider trading.[1] Kramer sold shares in the company and raised more than $10.1 million before the contamination of AstraZeneca's COVID-19 vaccine became public.[1][7] In 2020, Emergent signed a $261 million contract with AstraZeneca to produce the vaccine.[1] Emergent encountered production problems in which a large amount of the vaccine was contaminated and rendered unusable.[1] Kramer's business plan was approved by Emergent on November 13, 2020, and the share sale took place in January and February 2021.[1] Emergent reached a $900,000 punitive settlement with the attorney general's office and will improve its lead trading policies.[1][5] James is seeking damages, disgorgement and costs from Kramer for violating state securities laws.[1]